DITPA Dosing Regimen for AHDS Hormone Level Stabilization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Allan-Herndon-Dudley Syndrome (AHDS) are ineffective due to a lack of stable and effective dosing regimens for 3,5-diiodothyropropionic acid (DITPA), leading to difficulties in accurately assessing triiodothyronine (T3) serum levels and impacting thyroxine (T4) and thyroid stimulating hormone (TSH) levels.
Innovation Solution
Administering DITPA at specific dosages of about 2.5 milligrams per kilogram of body weight per day, adjusting based on triiodothyronine (T3) serum levels, to normalize T3 levels, increase T3 brain levels, and maintain normal thyroxine (T4) and thyroid stimulating hormone (TSH) levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If TRIAC is used to treat AHDS, then T3 serum levels can be reduced, but T4 serum levels are significantly reduced and it is difficult to accurately assess T3 serum levels
Solution Approach 1:
The patent introduces DITPA as an intermediary substance that mediates the treatment effect. DITPA serves as a proxy that can be measured to infer T3 status without directly interfering with T4 levels or creating measurement interference, thus resolving the contradiction between accurate T3 assessment and T4 stability.
Solution Approach 2:
The patent changes the measurement parameter from direct T3 measurement (which is interfered with by TRIAC) to DITPA measurement. This parameter substitution allows accurate assessment of thyroid hormone status without the measurement interference that occurs with TRIAC treatment, while maintaining T4 stability.
2Measurement precision
If DITPA is administered at high doses to reduce T3 serum levels, then T3 levels decrease, but T4 and TSH levels become unstable
Solution Approach 1:
The patent implements a feedback mechanism where DITPA dosing is adjusted based on measured T3 levels and T4/TSH stability. The dosing regimen dynamically responds to laboratory results, reducing the dose when T3 is sufficiently controlled to prevent T4 and TSH instability, thus resolving the contradiction between T3 control and hormonal stability.
Solution Approach 2:
The patent transitions from static dosing to dynamic dosing regimens. The DITPA dose is continuously adjusted based on individual patient response and hormonal profile, allowing optimal T3 control while maintaining T4 and TSH stability through adaptive dosing rather than fixed high doses.
3Adaptability or versatility
If no treatment regimen is established for DITPA, then treatment flexibility is maintained, but effective dosing cannot be achieved
Solution Approach 1:
The patent segments the treatment approach into distinct phases: initial dosing phase, monitoring phase, and dose adjustment phase. This segmentation allows flexibility in individual patient management while establishing reliable dosing guidelines, resolving the contradiction between treatment adaptability and effectiveness.
Data Source
AI summary
The present subject matter is directed to methods of treating Allan-Herndon-Dudley syndrome comprising administering 3,5-diiodothyropropionic acid (DITPA) to a subject in need thereof, wherein the DITPA administration reduces triiodothyronine (“T3”) serum levels to normal, increases T3 brain levels to normal, and maintains normal serum levels of thyroxine (T4) and thyroid stimulating hormone (TSH). The subject may be a child or an adult.